logo-loader
viewInnovus Pharmaceuticals

Innovus Pharma buys Beyond Human assets for US$630

Beyond Human’s most well-known products include a natural testosterone booster supplement and natural Human Growth Agent HGA.

shutterstock_144658310.jpg
Innovus Pharmaceuticals is an over the counter respiratory health product specialist

Over the counter respiratory health product specialist Innovus Pharmaceuticals, (OTC:INNV), has agreed to buy all assets from Texas-based Beyond Human LLC for US$630,000.

Innovus said, following the new all-cash deal, it expects its annual revenue to triple to close to US$4.0mln and will help it become cash flow positive in the near future.

Dr Bassam Damaj, chief executive of Innovus Pharma, said the deal was a “transformative acquisition,” adding that “with this acquisition, we will have a total of 14 products now in the fields of men and women health and we believe that Innovus Pharma will become a strong player in this category.”

Beyond Human’s most well-known products include the natural testosterone booster supplement Beyond T Human and its natural Human Growth Agent HGA.

Its sales, which are concentrated in the US, have been growing at almost 50% per year for the last two years, and in 2015, the firm had over US$2.2mln in gross revenues and net profit of US$400,000.

According to market experts, the US testosterone replacement market grew from US$1.6bn in 2011 to US$2.4bn in 2013 and is expected to hit US$3.8 billion in 2018.

Quick facts: Innovus Pharmaceuticals

Price: 1.55 USD

OTCMKTS:INNV
Market: OTCMKTS
Market Cap: $4.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

2 days, 3 hours ago

2 min read